glp-1 obesity drug news today Study flags need to monitor frailty risks with drugs for older adults GLP-1 medications could cut US
Description
This study follows the recommendations of the reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV) 16
[DOI] [PubMed] [Google Scholar] 196.Dejgaard T.F., Schmidt S., Frandsen C.S., Vistisen D., Madsbad S., Andersen H.U
[DOI] [PubMed] [Google Scholar] 137.Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, et al
Predominantly gastrointestinal nausea, diarrhea, vomiting, constipation, and decreased appetite all dose-dependent and most common after a dose or an escalation
Regarding safety, the most common adverse events associated with Retatrutide were gastrointestinal-related
Liu T et al
